CCR2 and hepatocellular carcinoma: Therefore, targeting chemokine receptor CCR2 and its ligands for treating chronic liver disease and HCC has excellent prospects, especially in combination with immunotherapy, and further studies in preclinical animal models and liver disease patients’ clinical data are required.